Bachem Expands Peptide Manufacturing Capacity in Switzerland
2025-01-15
Bachem announces major expansion of peptide manufacturing facilities in Switzerland, featuring state-of-the-art SPPS and LPPS capabilities to meet growing global API demand.
Bachem Holding AG, a leading peptide manufacturer, announced a major expansion of its Swiss manufacturing facilities to meet rising international demand for peptide APIs. The new facility will feature state-of-the-art solid-phase peptide synthesis (SPPS) and liquid-phase peptide synthesis (LPPS) capabilities, enabling the production of complex peptides at greater scale and efficiency.
The expansion includes a new site in Sisslerfeld focused on large-scale peptide manufacturing, ensuring continued supply to meet market demands for decades to come. Building K expansion is expected to go live in H2 2025.
This strategic investment reinforces Bachem's position as the preferred partner for large-scale commercial peptide manufacturing, with new multi-year supply agreements with pharmaceutical companies developing GLP-1 analogs and other metabolic disease peptide therapeutics.
Read Full Source Article